Virology division end date??

[anonymous]

Why wouldn't they??? It's an easy gig despite the fact that the products are mature. But yeah, if they aren't looking around they would be foolish in my humble opinion. The problem is that there are fewer and fewer companies in the space anymore.

Again, lazy sloths as they aren't willing to look outside their comfy zone of the past 10-15 years. Try re-inventing yourself every once in awhile.

 

[anonymous]

The rude awakening is that no employers wants HIV or ID reps -they won't have any relevant experience in a competitive job market

 

[anonymous]

The rude awakening is that no employers wants HIV or ID reps -they won't have any relevant experience in a competitive job market

Well said, exactly the sentiment out there. Those of you who think your decade plus of dedication to the HIV field sets you apart, you're dreaming. For the most part, you're so far behind the pack, you'll have egg on your face in an interview for a relevant position trying to articulate why you stayed with a has-been market place.

 

[anonymous]

Well said, exactly the sentiment out there. Those of you who think your decade plus of dedication to the HIV field sets you apart, you're dreaming. For the most part, you're so far behind the pack, you'll have egg on your face in an interview for a relevant position trying to articulate why you stayed with a has-been market place.

You're absolutely right. Nobody has HIV anymore. It's not even a has-been marketplace, it's a never-was. It's all a government conspiracy!

 

[anonymous]

There is a virology division ?????

Yes there is a Virology division.
Virology accounted for over $4 billion or 222% of revenues in 2016.

 

[anonymous]

Yes there is a Virology division.
Virology accounted for over $4 billion or 222% of revenues in 2016.

Yes there is a Virology division.
Virology accounted for over $4 billion or 22% of revenues in 2016.

 

[anonymous]

Yes there is a Virology division.
Virology accounted for over $4 billion or 22% of revenues in 2016.

Just never hear anything about this group

 

[anonymous]

Again, lazy sloths as they aren't willing to look outside their comfy zone of the past 10-15 years. Try re-inventing yourself every once in awhile.

don't blame reps you donut boy! use that mountain scent Gain on your face

 

[anonymous]

Just never hear anything about this group

Always been that way, even when virology was contributing the most. Sad to see what it's become

 

[anonymous]

Always been that way, even when virology was contributing the most. Sad to see what it's become

China Approves Bristol-Myers Squibb’s Dual-Drug Hepatitis C Treatment.

 

[anonymous]

China Approves Bristol-Myers Squibb’s Dual-Drug Hepatitis C Treatment.

Who cares. HCV gone. HIV soon to follow. Unless they want to transfer the sales force to China.

 

[anonymous]

Who cares. HCV gone. HIV soon to follow. Unless they want to transfer the sales force to China.

“We are proud to build on our legacy, infrastructure and experience in treating viral hepatitis throughout Asia by bringing Daklinza-based regimens to patients in China,” said Murdo Gordon, executive vice president and chief commercial officer, Bristol-Myers Squibb.

 

[anonymous]

“We are proud to build on our legacy, infrastructure and experience in treating viral hepatitis throughout Asia by bringing Daklinza-based regimens to patients in China,” said Murdo Gordon, executive vice president and chief commercial officer, Bristol-Myers Squibb.

Did he also say that will have any effect on the virology salesforce in the US? I didn't think so.

 

[anonymous]

Did he also say that will have any effect on the virology salesforce in the US? I didn't think so.

Ximency (daclatasvir + asunaprevir + beclabuvir) in Japan, aiming to regain its lost ground in the genotype 1 market.

 

[anonymous]

Ximency (daclatasvir + asunaprevir + beclabuvir) in Japan, aiming to regain its lost ground in the genotype 1 market.

Only one of those three saw the light of day in the US and at less than 2 years after approval of it, it has already become obsolete.

 

[anonymous]

Only one of those three saw the light of day in the US and at less than 2 years after approval of it, it has already become obsolete.

Around $1.1 billion in Virology revenues in 1Q2017.
Not bad for a division that was closed 2 years ago.

 

[anonymous]

Date of euthanasia was put out today.

 

[anonymous]

Who even knew BMS had a virology division????

 

[anonymous]

Who even knew BMS had a virology division????

HA HA!!!!
Indeed....like R&D.....
Mostly "make something out of this crap we've already paid for"!!!!!!

 

[anonymous]

Lambda